Table 2.
Basal characteristics of patients with metastatic breast cancer.
| Parameter | Total N = 126 (%) |
Metastatic site | p value | |||
|---|---|---|---|---|---|---|
| Bone N = 31 (%) |
Brain N = 36 (%) |
Liver N = 11 (%) |
Lung N = 48 (%) |
|||
| Age (years) | ||||||
| ≤50 | 65 (51.6) | 17 (54.8) | 17 (47.2) | 4 (36.4) | 27 (56.3) | 0.605 |
| >50 | 61 (48.4) | 14 (45.2) | 19 (52.8) | 7 (63.6) | 21 (43.8) | |
| ER | ||||||
| Negative | 59 (46.8) | 6 (19.4) | 25 (69.4) | 2 (18.2) | 26 (54.2) | <0.001 |
| Positive | 67 (53.2) | 25 (80.6) | 11 (30.6) | 9 (81.8) | 22 (45.8) | |
| PR | ||||||
| Negative | 86 (68.3) | 16 (51.6) | 35 (97.2) | 3 (27.3) | 32 (66.7) | <0.001 |
| Positive | 40 (31.7) | 15 (48.4) | 1 (2.8) | 8 (72.7) | 16 (33.3) | |
| HER-2 | ||||||
| Negative | 86 (68.3) | 25 (80.6) | 18 (50.0) | 9 (81.8) | 34 (70.8) | 0.032 |
| Positive | 40 (31.7) | 6 (19.4) | 18 (50.0) | 2 (18.2) | 14 (29.2) | |
| Ki-67 LI | ||||||
| <14 | 84 (66.7) | 27 (87.1) | 18 (50.0) | 9 (81.8) | 30 (62.5) | 0.008 |
| ≥14 | 42 (33.3) | 4 (12.9) | 18 (50.0) | 2 (18.2) | 18 (37.5) | |
| Molecular subtype | ||||||
| Luminal A | 44 (34.9) | 21 (67.7) | 3 (8.3) | 6 (54.5) | 14 (29.2) | <0.001 |
| Luminal B | 24 (19.0) | 5 (16.1) | 8 (22.2) | 3 (27.3) | 8 (16.7) | |
| HER-2 | 25 (19.8) | 3 (9.7) | 12 (33.3) | 1 (9.1) | 9 (18.8) | |
| TNBC | 33 (26.2) | 2 (6.5) | 13 (36.1) | 1 (9.1) | 17 (35.4) | |
| Patient death | 41 (32.5) | 16 (51.6) | 11 (30.6) | 4 (36.4) | 10 (20.8) | 0.041 |
ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor-2; LI, labeling index; TNBC, triple negative breast cancer.